Covidien to repurchase $3B more in company shares

03/25/2013 | Clinica (subscription required)

A plan by Covidien to buy back $3 billion of its stock has been approved by the company's board, a move expected to benefit shareholders over the short term. In August 2011, the company also initiated a similar repurchase program, worth $2 billion.

View Full Article in:

Clinica (subscription required)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT